A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors With an Alteration of the PIK3CA Gene|Estrogen Receptor Positive Breast Cancer
Interventions: DRUG: BYL719|DRUG: Fulvestrant
Sponsor: Novartis Pharmaceuticals